E156 Micro-Paper · Africa Clinical Trials

Diabetes Epidemic Mismatch

Africa's diabetes epidemic is accelerating faster than any other continent, driv...

Africa Trials
760
US Trials
8,095
Gap Ratio
11x
Nations
54
Africa hosted 760 diabetes trials versus 8,095 in the United States, a 11-fold disparity in research investment.
Burden vs Investment 2000 4000 6000 8000 50000 100000 150000 Africa US Europe
Diabetes Epidemic Mismatch Lorenz Curve 0% 0% 25% 25% 50% 50% 75% 75% 100% 100% Gini = 0.711
Diabetes Epidemic Mismatch by Country Egypt: 11752 Algeria: N/A Morocco: 162 Tunisia: 540 Senegal: N/A Ghana: 261 Nigeria: 379 Cameroon: N/A DRC: N/A Ethiopia: 302 Kenya: 788 Uganda: 809 Tanzania: 460 Rwanda: N/A South Africa: 3654 Egy 11752 Sou 3654 Uga 809 Ken 788 Tun 540 162 11752
No data
Contribution Breakdown 11752 Egypt 3654 South Afri 809 Uganda 788 Kenya 540 Tunisia 2814 Others
Research Profile Volume Growth Phase3 Complete Diversity
Enrollment Distribution Africa Reference 10000 20000 30000
Regional Comparison Africa US Europe 0 2000 4000 6000 8000 10000
Why It Matters

Africa's diabetes epidemic is accelerating faster than any other continent, driven by urbanization and dietary shifts, yet diabetes trial infrastructure barely exists outside South Africa and Egypt.

In the burden-versus-investment landscape of African health research, does the distribution of diabetes trials across African nations reveal a systematic research gap? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the linear regression slope as the primary estimand using registry metadata for each nation. Africa hosted 760 diabetes trials (3.2% of its portfolio) compared to 8,095 in the United States, yielding a 0.0-fold disparity in per-population investment. Temporal analysis showed 17.1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted. These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa. Interpretation is limited by reliance on ClinicalTrials.gov alone, which may undercount locally registered African studies.
Question

In the burden-versus-investment landscape of African health research, does the distribution of diabetes trials across African nations reveal a systematic research gap?

Dataset

This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.

Method

gov through April 2026.

Primary Result

Investigators computed the linear regression slope as the primary estimand using registry metadata for each nation.

Robustness

Africa hosted 760 diabetes trials (3.

Interpretation

2% of its portfolio) compared to 8,095 in the United States, yielding a 0.

Boundary

0-fold disparity in per-population investment.

Extra

Temporal analysis showed 17.

Extra

1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted.

Extra

These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa.

Extra

Interpretation is limited by reliance on ClinicalTrials.

Extra

gov alone, which may undercount locally registered African studies.